GLP-1 Users Test Younger

BostonGLP-1 users test 2 to 3 years biologically younger.

The makers, Eli Lilly and Novo Nordisk, presented the findings at an ageing meeting in Boston.

Overweight and diabetic people on GLP-1s were compared with similar people on placebo, and only some measures of biological age shifted.

Dozens are suing Novo Nordisk and Eli Lilly over sudden vision loss, which both dispute.

Prescriptions for US children aged 8 to 11 rose 310-fold by 2026, and their side-effect data is thin.

How each outlet framed it

MIT Technology Review: reads the Gallup 11% GLP-1 use figure as a sign of how widely the drugs are taken